bioMérieux Yönetim

Pierre Boulud'un ücretlendirmesi bioMérieux'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	€411m
Mar 31 2024	n/a	n/a	€384m
Dec 31 2023	€2m	€631k	€358m
Sep 30 2023	n/a	n/a	€372m
Jun 30 2023	n/a	n/a	€386m
Mar 31 2023	n/a	n/a	€419m
Dec 31 2022	€2m	€510k	€452m
Sep 30 2022	n/a	n/a	€502m
Jun 30 2022	n/a	n/a	€552m
Mar 31 2022	n/a	n/a	€577m
Dec 31 2021	€2m	€510k	€601m
Sep 30 2021	n/a	n/a	€555m
Jun 30 2021	n/a	n/a	€509m
Mar 31 2021	n/a	n/a	€457m
Dec 31 2020	€1m	€497k	€404m

Tazminat ve Piyasa: Pierre 'nin toplam tazminatı ($USD 2.67M ), French pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 4.77M ).

Tazminat ve Kazançlar: Pierre 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Pierre Boulud (53 yo)

1.3yrs

Görev süresi

€2,452,864

Tazminat

Mr. Pierre Boulud is Chief Executive Officer of bioMérieux S.A. from July 01, 2023. He served as Chief Operating Officer of Clinical Operations at BioMérieux S.A. until 2023 and served as its Chief Operati...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pierre Boulud	Chief Executive Officer	1.3yrs	€2.45m	Veri yok
Guillaume Bouhours	Executive VP of Purchasing and Information Systems & CFO	6.7yrs	Veri yok	Veri yok
Sylvain Morgeau	Investor Relations	no data	Veri yok	Veri yok
Audrey Dauvet	Executive Vice President of Legal	1.8yrs	Veri yok	Veri yok
Valerie Leylde	Executive Vice President of Human Resources	5.8yrs	Veri yok	Veri yok
Pierre Charbonnier	Executive Vice President of Global Quality	6.7yrs	Veri yok	Veri yok
Yasha Mitrotti	Executive Vice President of Industrial Applications	6.7yrs	Veri yok	Veri yok
Frederic Beseme	Head of CSR	4.8yrs	€21.99k	Veri yok
Jennifer Zinn	Executive Vice President of Clinical Operations	1.3yrs	Veri yok	Veri yok
Charles Cooper	Executive VP & Chief Medical Officer	less than a year	Veri yok	Veri yok
Celine Roger-Dalbert	Executive Vice President of Research & Development	less than a year	Veri yok	Veri yok
Franck Admant	Director of Investor Relations	no data	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: BIM 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alain Merieux	Founding Chairman	7.3yrs	Veri yok	Veri yok
Jean-Luc Belingard	Non-Independent Director	18.2yrs	€52.00k	0.051% € 6.2m
Philippe Archinard	Non-Independent Director	14.4yrs	€61.00k	0.000030% € 3.6k
Alexandre Merieux	Chairman	20.6yrs	€1.92m	0.000050% € 6.0k
Harold Y. Boel	Independent Director	12.5yrs	€56.00k	0.00013% € 15.7k
Marie-Helene Habert-Dassault	Independent Director	12.5yrs	€44.00k	0.000050% € 6.0k
Fanny Letier	Independent Director	7.5yrs	€61.17k	0.000030% € 3.6k
Viviane Monges	Independent Director	less than a year	Veri yok	Veri yok
Marie-Paule Kieny	Independent Director	7.3yrs	€35.00k	0.00015% € 18.1k
Sylvain Orenga	Employee Representative Director	2.5yrs	€52.00k	Veri yok

10.0yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BIM 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10 yıldır).

bioMérieux Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

bioMérieux S.A., Annual General Meeting, May 23, 2024

Insufficient new directors

bioMérieux S.A., Annual General Meeting, May 23, 2022

Recent updates

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?

bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

First half 2024 earnings: EPS and revenues exceed analyst expectations

Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

bioMérieux Announces USDA-FSIS Field Service Laboratories Selects GENE-UP Pathogenic E. coli Assay as Primary Method for Shiga Toxin-Producing E. coli Detection

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Upcoming dividend of €0.85 per share

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)

bioMérieux S.A. to Report First Half, 2024 Results on Sep 05, 2024

Now 21% undervalued

bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings

New minor risk - Earnings quality

Dividend of €0.85 announced

bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

bioMérieux S.A., Annual General Meeting, May 23, 2024

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward

A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger

There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

First half 2023 earnings released: EPS: €1.37 (vs €1.93 in 1H 2022)

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down

Upcoming dividend of €0.85 per share at 0.9% yield

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Third quarter 2022 earnings released: EPS: €0.95 (vs €1.37 in 3Q 2021)

The Return Trends At bioMérieux (EPA:BIM) Look Promising

bioMérieux Introduces GENE-UP ENVIROPRO

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

bioMérieux S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023

bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet

bioMérieux and Jackson Family Wines Introduces Innovation for Wine Quality - BOTTLESAFE™

bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: €1.93 (vs €2.34 in 1H 2021)

Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital

Now 20% undervalued

An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued

Now 22% undervalued

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Upcoming dividend of €0.85 per share

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

Insufficient new directors

bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

bioMérieux S.A., Annual General Meeting, May 23, 2022

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire remaining unknown shares in Specific Diagnostics, LLC for €360 million.

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire Specific Diagnostics, LLC.

bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Price target decreased to €118

Full year 2021 earnings: EPS and revenues exceed analyst expectations

I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease

Why We Like The Returns At bioMérieux (EPA:BIM)

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Price target increased to €124

Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching

Is bioMérieux (EPA:BIM) A Risky Investment?

bioMérieux Achieves First-Ever AOAC INTERNATIONAL Approval for PCR Multiplex Detection of STEC and Salmonella in Cannabis Flower for the GENE-UP® PRO STEC/ Salmonella Assay

Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital